ASX:NTI

Stock Analysis Report

Neurotech International

Executive Summary

Neurotech International Limited engages in the research, design, development, and manufacture of medical devices and solutions in Australia.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Neurotech International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NTI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

33.3%

NTI

12.0%

AU Medical Equipment

5.1%

AU Market


1 Year Return

-60.0%

NTI

12.0%

AU Medical Equipment

-19.0%

AU Market

Return vs Industry: NTI underperformed the Australian Medical Equipment industry which returned 12% over the past year.

Return vs Market: NTI underperformed the Australian Market which returned -19.2% over the past year.


Shareholder returns

NTIIndustryMarket
7 Day33.3%12.0%5.1%
30 Day-42.9%-12.8%-20.9%
90 Day-76.5%-16.3%-25.6%
1 Year-60.0%-60.0%14.1%12.0%-15.4%-19.0%
3 Year-98.6%-98.7%30.2%24.0%-3.3%-16.6%
5 Yearn/a71.6%56.9%6.9%-17.3%

Price Volatility Vs. Market

How volatile is Neurotech International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Neurotech International undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Neurotech International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Neurotech International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of NTI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Neurotech International regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Neurotech International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Neurotech International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Neurotech International performed over the past 5 years?

-13.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NTI is currently unprofitable.

Growing Profit Margin: NTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NTI is unprofitable, and losses have increased over the past 5 years at a rate of -13.1% per year.

Accelerating Growth: Unable to compare NTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).


Return on Equity

High ROE: NTI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Neurotech International's financial position?


Financial Position Analysis

Short Term Liabilities: NTI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NTI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NTI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: NTI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: NTI has a low level of unsold assets or inventory.

Debt Coverage by Assets: NTI has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NTI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NTI has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.3% each year.


Next Steps

Dividend

What is Neurotech International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NTI's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Peter James Griffiths (55yo)

1.42s

Tenure

AU$316,067

Compensation

Mr. Peter James Lawrence Griffiths, B.Sc. (Hons), has been the Chief Executive Officer and Managing Director at Neurotech International Limited since November 26, 2018. Mr. Griffiths a Senior Advisor at Br ...


CEO Compensation Analysis

Compensation vs Market: Peter James's total compensation ($USD189.93K) is about average for companies of similar size in the Australian market ($USD238.58K).

Compensation vs Earnings: Peter James's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Peter James Griffiths
Deputy Chairman1.42yrsAU$316.07k5.22% A$29.2k
Emanuela Russo
Chief Scientific Officer & Member of Scientific Advisory Boardno datano datano data
Erlyn Dale
Company Secretary1yrno datano data

1.4yrs

Average Tenure

Experienced Management: NTI's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Peter James Griffiths
Deputy Chairman1.42yrsAU$316.07k5.22% A$29.2k
Emanuela Russo
Chief Scientific Officer & Member of Scientific Advisory Boardno datano datano data
Evian Gordon
Member of Scientific Advisory Board1.5yrsno datano data
Winton Willesee
Independent Non-Executive Director1yrAU$8.45k0.24% A$1.4k
Mark Davies
Independent Non-Executive Chairman1yrAU$10.83kno data
David Cantor
Chairman of Scientific Advisory Board & Non-Executive Directorno dataAU$69.67k0.10% A$571.4
Tanju Surmeli
Member of Scientific Advisory Board1.5yrsno datano data

1.3yrs

Average Tenure

Experienced Board: NTI's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.4%.


Top Shareholders

Company Information

Neurotech International Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Neurotech International Limited
  • Ticker: NTI
  • Exchange: ASX
  • Founded: 2016
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$558.926k
  • Shares outstanding: 139.73m
  • Website: https://www.neurotechinternational.com

Location

  • Neurotech International Limited
  • 145 Stirling Highway
  • Suite 5 CPC
  • Nedlands
  • Western Australia
  • 6009
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NTIASX (Australian Securities Exchange)YesOrdinary SharesAUAUDNov 2016
NTICHIA (Chi-X Australia)YesOrdinary SharesAUAUDNov 2016
NTIL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2016

Biography

Neurotech International Limited engages in the research, design, development, and manufacture of medical devices and solutions in Australia. Its product, Mente Autism, is a portable electroencephalogram medical device that uses neurofeedback to help relax the minds of children with autism spectrum disorder. The company focuses on developing neuro-stimulation and neuro-diagnostic solutions that enable medical practitioners to monitor and play an active role in home-based therapies. It also engages in executing medical research projects and developing technological devices; and publishing, registering, and maintaining intellectual property. The company was incorporated in 2016 and is based in Nedlands, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/05 10:46
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.